Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 14/20 | 0.73 |
| ▸ | ACP1 | P24666 | 1/20 | 0.44 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.44 |
| ▸ | PTPN13 | Q12923 | 1/20 | 0.44 |
| ▸ | SSU72 | Q9NP77 | 1/20 | 0.44 |
| ▸ | PNLIP | P16233 | 2/20 | 0.41 |
| ▸ | UGCG | Q16739 | 1/20 | 0.40 |
| ▸ | PARG | Q86W56 | 1/20 | 0.39 |
| ▸ | STK39 | Q9UEW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1372993 | 1.00 | S1PR1 (0.73) | S1PR1ACP1PTPN12PTPN13SSU72 | |
| SCHEMBL1375560 | 0.96 | S1PR1 (0.68) | S1PR1ACP1PTPN12PTPN13SSU72 | |
| SCHEMBL1375562 | 0.96 | S1PR1 (0.68) | S1PR1ACP1PTPN12PTPN13SSU72 | |
| SCHEMBL12044755 | 0.89 | S1PR1 (0.72) | S1PR1 | |
| SCHEMBL1373398 | 0.87 | S1PR1 (0.62) | S1PR1 | |
| SCHEMBL1373400 | 0.87 | S1PR1 (0.62) | S1PR1 | |
| SCHEMBL1375617 | 0.86 | S1PR1 (0.72) | S1PR1 | |
| SCHEMBL1375620 | 0.86 | S1PR1 (0.72) | S1PR1 | |
| SCHEMBL1373781 | 0.84 | S1PR1 (0.60) | S1PR1 | |
| SCHEMBL1373785 | 0.84 | S1PR1 (0.60) | S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802692-B2 | Synergistic effects between sphingosine-1-phosphate receptor antagonists and antimicrotubule agents | EXELIXIS, INC. (US) | 2014-08-12 | — | — | US | claimed |
| US-8802692-B2 | Synergistic effects between sphingosine-1-phosphate receptor antagonists and antimicrotubule agents | EXELIXIS, INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-8791102-B2 | Acetanilide sphingosine-1-phosphate receptor antagonists | EXELIXIS, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-20110301188-A1 | Synergistic Effects Between Sphingosine-1-Phosphate Receptor Antagonists and Antimicrotubule Agents | EXELIXIS, INC. (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110288076-A1 | Sphingosine-1-Phosphate Receptor Antagonists | EXELIXIS, INC. (US) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301188-A1 | Synergistic Effects Between Sphingosine-1-Phosphate Receptor Antagonists and Antimicrotubule Agents | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885ACP1 1679/4885PTPN12 1494/4885 |
| US-20110288076-A1 | Sphingosine-1-Phosphate Receptor Antagonists | S1PR1, S1PR2, S1PR3 | S1PR1 1/4885ACP1 417/4885PTPN12 1683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.